CMS finalizes rule offering flexibility in 2014 CEHRT

The Centers for Medicare & Medicaid Services (CMS) has finalized a rule that provides flexibility in how healthcare providers can use certified EHR technology (CEHRT) for the 2014 EHR Incentive Program reporting period. However, moments after release, some stakeholders already are questioning whether it goes far enough.

Under the final rule, eligible providers can use the 2011 Edition CEHRT or a combination of 2011 and 2014 Edition CEHRT for an EHR reporting period in 2014 for the EHR incentive program. The rule also finalizes the extension of Stage 2 through 2016 for certain providers and announces the Stage 3 timeline, which will begin in 2017 for providers who first became meaningful EHR users in 2011 or 2012, according to CMS.

All eligible professionals, eligible hospitals and critical access hospitals are required to use the 2014 Edition CEHRT in 2015.

The added flexibility will allow providers to participate and meet Meaningful Use objectives like drug interaction and drug allergy checks, providing clinical summaries to patients, electronic prescribing, reporting on key public health data and reporting on quality measures, according to the agency.

"We listened to stakeholder feedback and provided CEHRT flexibility for 2014 to help ensure providers can continue to participate in the EHR Incentive Programs forward," said CMS Administrator Marilyn Tavenner in a statement. "We were excited to see that there is overwhelming support for this change."

In comments issued shortly following the rule’s release on the afternoon of Aug. 29, the College of Healthcare Information Management Executives President and CEO Russell P. Branzell said he was “deeply disappointed” in the decision made by CMS and the Office of the National Coordinator for Health IT to require 365 days of EHR reporting in 2015.

“This single provision has severely muted the positive impacts of this final rule. Further, it has all but ensured that industry struggles will continue well beyond 2014,” he wrote.

This is a developing story.



 



 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.